Intellipharmaceutics

157 articles with Intellipharmaceutics

• Intellipharmaceutics Meets with FDA Regarding Oxycodone ER NDA Development Program

  2/12/2018

  Intellipharmaceutics today announced that it held a meeting with the United States FDA regarding the Company's abuse-deterrent oxycodone hydrochloride extended release tablets product candidate.

• Intellipharmaceutics Provides Operational Update - Jan. 24, 2018

  1/24/2018

  The company provided an operational update on its plans and projected timelines for the 2018 year.

• Intellipharmaceutics Announces Receipt of Nasdaq Notice - Dec. 5, 2017

  12/5/2017

  The Notification Letter does not impact the Company's listing on The Nasdaq Capital Market at this time.

• Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR by Par Pharmaceutical

  11/30/2017

  The launch of the 5 and 40 mg strengths complements the 10, 15, 20, 25, 30 and 35 mg strengths of generic Focalin XR previously launched and marketed by Par.

• Intellipharmaceutics Announces Closing of $4M Financing

  10/16/2017

  Intellipharmaceutics announced today the closing of its previously announced registered direct offering consisting of 3,636,364 common shares at a price of US$1.10 per share for gross proceeds of approximately US$4 million.

• Intellipharmaceutics Announces US$4 Million Registered Direct Offering

  10/11/2017

• FDA Turns Down Intellipharmaceutics's Opiod Painkiller Rexista

  9/25/2017

• Intellipharmaceutics Announces Receipt Of Nasdaq Notice

  9/21/2017

• Intellipharmaceutics Provides Operational Update

  9/6/2017

• Intellipharmaceutics Appoints New Chief Financial Officer

  9/1/2017

• Intellipharmaceutics Announces Resignation Of Chief Financial Officer

  8/9/2017

• Intellipharmaceutics Intends To Vigorously Defend Recently Filed Purported Class Action Lawsuit

  7/31/2017

• Intellipharmaceutics Provides Update On FDA Advisory Committees Meeting For Rexista (Oxycodone Hydrochloride Extended Release), An Abuse-Deterrent Opioid Analgesic For The Treatment Of Moderate To Severe Pain

  7/27/2017

• Intellipharmaceutics Announces Second Quarter 2017 Results

  7/12/2017

• Intellipharmaceutics Announces Launch Of Generic Seroquel XR By Mallinckrodt

  6/6/2017

• Intellipharmaceutics Files Preliminary Base Shelf Prospectus And Shelf Registration Statement To Replace Expiring Shelf Registration Statement

  5/30/2017

• Intellipharmaceutics Reports On Launch Of Additional Strengths Of Generic Focalin XR By Par Pharma

  5/25/2017

• Intellipharmaceutics Announces FDA Final Approval Of Generic Seroquel XR

  5/11/2017

• Intellipharmaceutics Reports Director Election Results

  4/19/2017

• Intellipharmaceutics Announces First Quarter 2017 Results

  4/12/2017